Clinical trials of myocardial revascularization for acute myocardial infarction in all type of patients

TrialResults-center www.trialresultscenter.org

1 deferred angioplasty (>3 days) after thrombolysis

Trial	Treatments	Patients	Trials design and methods
systematic ballon angioplasty vs no systematic angioplasty			
SWIFT , 1991 n=397/403 follow-up: 1 y	CA 72h with a view to PTCA or CABG versus elective angioplasty (only if required by clinical indication)	patients presenting with clinical and electrocardiographic features of acute myocardial infarction up to three hours after the onset of major symptoms	Parallel groups Open UK
SIAM , 1992 n=158/166 follow-up: <3 years	CA with CABG/PTCA 14-48 hours versus no CA within the first 21days unless evidence of ischemia	patients treated by thrombolysis for AMI	Parallel groups Open Europe
TAMI 6 , 1992 n=34/37	PTCA 6-24h after rtPA versus no PTCA planned	-	
Barbash , 1990 n=97/104	PTCA>72h after rtPA if stenosis>70% versus PTCA>72h after rtPA if stenosis>50% and ischemia	-	
Guerci , 1987 n=42/43 follow-up: 10 days	PTCA at 4 day versus no PTCA during the 10 days study period	patients candidate to PTCA determined at the 1st day CA	Factorial plan United states
TIMI 2 , 1989 n=1636/1626 follow-up: 6 we	CA 18 to 48 hrs versus no CA unless spontaneous or exercise induced ischemia	patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) within four hours of the onset of chest pain thought to be caused by myocardial infarction	Factorial plan Open United states
TIMI II-A (defered) n=194/197 follow-up:	delayed invasive strategy, deferred angiography and PTCA for 18-48 hours versus conservative approach	-	
TOPS , 1992 n=42/45 follow-up: 12 months	PTCA to be performed 4-14 days after MI versus conservative management, no PTCA	patients with residual stenoses after thrombolytic treatment of myocardial infarction	Parallel groups
Van den Brand , 1991 n=113/104 follow-up: 3 mo	CA at 2-5 days, PTCA if suitable lesion versus CA at 2-5 days but no PTCA	suitable lesion	Parallel groups NA Europe

Trial	Treatments	Patients	Trials design and methods
Vermeer , 1999 n=NA follow-up: 42 days	alteplase followed by transfer to the PTCA centre and (if indicated) rescue PTCA versus thrombolytic treatment with alteplase	patients with acute myocardial infarction initially admitted to a hospital without PTCA facilities	Parallel groups

References

SWIFT, 1991:

, SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. BMJ 1991; 302:555-60 [2021717]

SIAM, 1992:

JACC 1992 19:239A(abstract) [0]

TAMI 6, 1992:

Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O'Brien M, Schwaiger M, Aguirre FV A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. Circulation 1992 Jun;85:2090-9 [1591828]

Barbash, 1990:

Barbash GI, Roth A, Hod H, Modan M, Miller HI, Rath S, Zahav YH, Keren G, Motro M, Shachar A Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1990 Sep 1;66:538-45 [2118299]

Guerci, 1987:

Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE, et al, A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987; 317:1613-8 [2960897] 10.1056/NEJM198712243172601

TIMI 2, 1989:

, Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989; 320:618-27 [2563896] 10.1056/NEJM198903093201002

TIMI II-A (defered), 0:

Rogers WJ, Baim DS, Gore JM, Brown BG, Roberts R, Williams DO, Chesebro JH, Babb JD, Sheehan FH, Wackers FJ Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation 1990;81:1457-76 [2110033]

TOPS, 1992:

Ellis SG, Mooney MR, George BS, da Silva EE, Talley JD, Flanagan WH, Topol EJ Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Treatment of Post-Thrombolytic Stenoses (TOPS) Study Group. Circulation 1992 Nov;86:1400-6 [1423952]

Van den Brand, 1991:

Eur Heart J 1991;I296 (abstract) [0]

Vermeer, 1999:

Vermeer F, Oude Ophuis AJ, vd Berg EJ, Brunninkhuis LG, Werter CJ, Boehmer AG, Lousberg AH, Dassen WR, Br FW Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999;82:426-31 [10490554]

2 drug-eluting stents

Trial	Treatments	Patients	Trials design and methods
drug-eluting stents vs bare-metal stent			
DEDICATION , 2008 [NCT00192868] n=313/313 follow-up: 8 mo (15 mo, 3y)	DES currently used with or without distal protection versus BMS with or without distal protection	patients referred within 12 hours from symptom onset of an ST-elevation myocardial infarction	Factorial plan open Denmark.
PASEO , 2009 n=180/90 follow-up: 4.3 years	paclitaxel-eluting stents and sirolimus-eluting stents versus bare metal stent	patients with ST-elevation myocardial infarction within 12 hours from symptom onset	Parallel groups open
paclitaxel eluting stent vs bare-metal stent			
HAAMU-STENT , 2006 *unpublished* n=70/75 follow-up: 12 months	Taxus Express versus Bare-metal-stent	AMI - STEMI patients undergoing PCI	Parallel groups open Finland
HORIZONS-AMI Stent , 2008 n=2257/749 follow-up: 1 year	paclitaxel-eluting stents (Taxus) versus BMS (Express)	ST-elevation myocardial infarction	Factorial plan open
PASSION , 2006 [ISRCTN65027270] n=310/309 follow-up: 12 months (5y)	Taxus Express2 versus Express2 or Libert	Myocardial Infarction with ST-Segment Elevation	Parallel groups open The Netherlands
sirolimus eluting stent vs bare-metal stent			
Daz de la Llera , 2007 n=60/54 follow-up: 1y	sirolimus-eluting stents versus uncoated stents	primary percutaneous coronary intervention for acute myocardial infarction with ST-segment elevation	Parallel groups open Spain
MISSION , 2008 [ISRCTN62825862] n=158/152 follow-up: 12 months	Cypher versus Vision	primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h)	Parallel groups single-blind the Netherlands
SESAMI , 2007 [NCT00288210] n=160/160 follow-up: 12 months	Cypher versus BX stent, Cordis	AMI	Parallel groups open Italy
TYPHOON , 2006 [NCT00232830] n=356/359 follow-up: 12 months	Cypher or CypherSelect versus any commerciallyavailable uncoated stent	AMI	Parallel groups open Worldwide (15 countries)
sirolimus eluting stent vs paclitaxel eluting stent			
Di Lorenzo et al. , 2005 *unpublished* n=90/90 follow-up:	sirolimus versus paclitaxel	ST-segment elevation myocardial infarction	Parallel groups open

Trial	Treatments	Patients	Trials design and methods
Juwana , 2009 [ISRCTN90526229] n=196/201 follow-up: 9 months (12 months)	sirolimus coated Cypher stent versus paclitaxel coated Taxus stent	patients with STEMI undergoing primary PCI	Parallel groups open The Netherlands
PROSIT , 2006 n=154/154 follow-up: 1 year	SES Cordis versus PES Boston Scientific	AMI or persistent ischaemia 12-24h	Parallel groups open Korea
zotarolimus eluting stent vs paclitaxel eluting stent			
ZEST AMI (vs PES) , 2009 [NCT00422565] n=108/110 follow-up: 1 year (mean)	zotarolimus-eluting stent (Endeavor) versus paclitaxel-eluting stent (Taxus Libert)	Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours	open Korea
zotarolimus eluting stent vs sirolimus eluting stent			
ZEST AMI (vs SES) , 2009 [NCT00422565] n=108/110 follow-up: 1 year (mean)	zotarolimus-eluting stent (Endeavor) versus sirolimus-eluting stents (Cypher)	Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours	Parallel groups open Korea

References

DEDICATION, 2008:

Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klvgaard L, Kaltoft A, Andersen B, Thuesen H, Engstrm T, Btker HE, Saunamki K, Krusell LR, Jrgensen E, Hansen HH, Christiansen EH, Ravkilde J, Kber L, Kofoed KF, Terkelsen CJ, Lassen JF Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008 Sep 9;118:1155-62 [18725489]

Kaltoft A, Kelbk H, Thuesen L, Lassen JF, Clemmensen P, Klvgaard L, Engstrm T, Btker HE, Saunamki K, Krusell LR, Jrgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Kber L, Kofoed KF, Terkelsen CJ, Helqvist S Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Follow-Up of the Randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010 Jun 14;: [20688033] 10.1016/j.jacc.2010.05.009

PASEO, 2009:

Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv 2009 Jun;2:515-23 [19539255]

Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation 2009;120:964-72 [19720939]

HAAMU-STENT, 2006:

Tierala I, Syvaenne M, Kupari M Randomised comparison of apaclitaxel-eluting and a bare metal stent in STEMI-PCI. TheHAAMU-STENT-study Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics; Washington, DC;Oct 2227, 2006. Abstract 178.

HORIZONS-AMI Stent, 2008:

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011 Jun 25;377:2193-2204 [21665265] 10.1016/S0140-6736(11)60764-2

PASSION, 2006:

Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13 [16971717]

Daz de la Llera, 2007:
MISSION, 2008:
SESAMI, 2007:
TYPHOON, 2006:
Di Lorenzo et al., 2005:
Juwana, 2009:
PROSIT, 2006:
ZEST AMI (vs PES), 2009:
ZEST AMI (vs SES), 2009:

3 early angioplasty (<3 days) after thrombolysis

Trial	Treatments	Patients	Trials design and methods
systematic ballon angioplasty vs no systematic angioplasty			
SWIFT , 1991 n=397/403 follow-up: 1 y	CA 72h with a view to PTCA or CABG versus elective angioplasty (only if required by clinical indication)	patients presenting with clinical and electrocardiographic features of acute myocardial infarction up to three hours after the onset of major symptoms	Parallel groups Open UK
SIAM , 1992 n=158/166 follow-up: <3 years	CA with CABG/PTCA 14-48 hours versus no CA within the first 21days unless evidence of ischemia	patients treated by thrombolysis for AMI	Parallel groups Open Europe
TAMI 6 , 1992 n=34/37	PTCA 6-24h after rtPA versus no PTCA planned	-	
Barbash , 1990 n=97/104	PTCA>72h after rtPA if stenosis>70% versus PTCA>72h after rtPA if stenosis>50% and ischemia	-	
Guerci , 1987 n=42/43 follow-up: 10 days	PTCA at 4 day versus no PTCA during the 10 days study period	patients candidate to PTCA determined at the 1st day CA	Factorial plan United states
TIMI 2 , 1989 n=1636/1626 follow-up: 6 we	CA 18 to 48 hrs versus no CA unless spontaneous or exercise induced ischemia	patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) within four hours of the onset of chest pain thought to be caused by myocardial infarction	Factorial plan Open United states

Trial	Treatments	Patients	Trials design and methods
TIMI II-A (defered) n=194/197 follow-up:	delayed invasive strategy, deferred angiography and PTCA for 18-48 hours versus conservative approach	-	
TOPS , 1992 n=42/45 follow-up: 12 months	PTCA to be performed 4-14 days after MI versus conservative management, no PTCA	patients with residual stenoses after thrombolytic treatment of myocardial infarction	Parallel groups
Van den Brand , 1991 n=113/104 follow-up: 3 mo	CA at 2-5 days, PTCA if suitable lesion versus CA at 2-5 days but no PTCA	suitable lesion	Parallel groups NA Europe
Vermeer , 1999 n=NA follow-up: 42 days	alteplase followed by transfer to the PTCA centre and (if indicated) rescue PTCA versus thrombolytic treatment with alteplase	patients with acute myocardial infarction initially admitted to a hospital without PTCA facilities	Parallel groups

References

SWIFT, 1991:

SIAM, 1992:

TAMI 6, 1992:

Barbash, 1990:

Guerci, 1987:

TIMI 2, 1989:

TIMI II-A (defered), 0:

TOPS, 1992:

Van den Brand, 1991:

Vermeer, 1999:

4   fibrinolysis

Trial	Treatments	Patients	Trials design and methods
APSAC vs control			
APSIM , 1989 n=112/119 follow-up: 3 weeks	APSAC 30 U over 5 min versus control (conventional heparin therapy, 5,000 IU in a bolus injection)	patients with a first acute myocardial infarction within 5 h after the onset of symptoms	Parallel groups open France
urokinase vs control			
USIM , 1991 n=1128/1073 follow-up: in hospital	urokinase bolus dose of 1 million U repeated after 60 minutes plus heparin versus control (heparin alone)	patients with acute myocardial infarction within 4 hours of the onset of pain	Parallel groups open Italy

9

Trial	Treatments	Patients	Trials design and methods
APSAC vs placebo			
AIMS , 1988 n=624/634 follow-up: 1 y	APSAC 30U IV in 5 min versus Placebo	Hommes et femmes, <70 ans	Parallel groups double blind
German Multicenter Trial , 1988 n=162/151 follow-up: 28 jours	APSAC 30 units en IV en 5 min, puis hparine en IV (17 U/kg/h) 4 h aprs l'injection d'APSAC versus Hparine 5000 U en bolus en IV, puis 17 U/kg/h	Hommes et femmes, <70 ans	Parallel groups
streptokinase vs placebo			
EMERAS (7-12h) , 1993 n=2257/2277 follow-up:	intravenous streptokinase 1.5 MU versus placebo	patients presenting 7-12 h from symptom onset	Parallel groups double blind
EMERAS (all delay) , 1993 n=2257/2277 follow-up:	streptokinase 1.5 MU versus placebo	patients entering hospital up to 24 h after the onset of suspected acute myocardial infarction	Parallel groups double blind south america
GISSI I , 1986 n=5860/5852 follow-up: 1 y	Streptokinase 1.5 MU en perfusion IV en 1 heure versus usual care	patients within 12 h after the onset of symptoms and with no contraindications to SK	Parallel groups open
ISAM , 1986 n=859/882 follow-up: 21 days	1.5 million IU of streptokinase over 1h versus Placebo	patients within six hours after the onset of symptoms of myocardial infarction	Parallel groups double blind
ISIS 2 pilot , 1987 n=NA follow-up:	streptokinase 1.5 MU versus placebo	patients with suspected acute myocardial infarction	Parallel groups double blind
ISIS-2 (SK) , 1988 n=8592/8595 follow-up: 15 mo	1-hour intravenous infusion of 1.5 MU of streptokinase versus Placebo	patients within 24h of the onset of suspected acute myocardial infarction	plan factoriel 2*2 double blind
Western Washington Intravenous Trial , 1988 [NCT00000507] n=191/177 follow-up: 1.4 y	Streptokinase en IV, 1.5 M UI en 60 min aprs injection de benadryl 50 mg en IV et hydrocortisone 100 mg en IV; hparine en IV 1000 UI/h 2h aprs la streptokinase puis warfarine pendant au moins 3 mois versus Traitement standard, avec ou sans anticoagulant (dcid par le mdecin)	Hommes et femmes, <ou = 75 ans	Parallel groups
t-PA vs placebo			
ASSET , 1988 n=2516/2495 follow-up: 6 months	rt-PA 100 mg versus Placebo	patient with suspected acute myocardial infarction	Parallel groups double blind

Trial	Treatments	Patients	Trials design and methods
LATE , 1993 n=2836/2875 follow-up: 6 mo	intravenous alteplase (100 mg over 3 h) versus placebo	patients with symptoms and electrocardiographic criteria consistent with AMI between 6 and 24 h from symptom onset	Parallel groups double blind
TAMI 6 , 1992 n=96/101 follow-up: 6 months	tissue-type plasminogen activator 100 mg over 2 hours versus placebo	patients with 6 to 24 hours of symptoms and ECG ST elevation	Parallel groups double blind USA

bolus t-PA vs accelerated t-PA

COBALT , 1997 n=3585/3584 follow-up: 30 days	of 50 mg of alteplase over a period of 1 to 3 minutes followed 30 minutes later by a second bolus of 50 mg (or 40 mg for patients who weighed less than 60 kg). versus weight-adjusted, accelerated infusion of 100 mg of alteplase	patients with acute myocardial infarction	Parallel groups double blind

lanoteplase vs accelerated t-PA

InTIME-II , 2000 n=10038/5022 follow-up: 30 days	lanoteplase 120 KU. kg(-1) as a single intravenous bolus versus up to 100 mg accelerated alteplase given over 90 min	patients presenting within 6 h of onset of ST elevation acute myocardial infarction	Parallel groups double blind worldwide

reteplase vs accelerated t-PA

GUSTO III , 1997 n=10138/4921 follow-up: 30 days	reteplase, in two bolus doses or 10 MU each given 30 minutes apart versus alteplase, up to 100 mg infused over a period of 90 minutes	patients within 6 hours after the onset of symptoms with ST-segment elevation or bundle-branch block	Parallel groups open 20 countries
RAPID-2 , 1996 n=169/155 follow-up: 35 days	10 plus 10 megaunits double bolus of reteplase versus front-loaded alteplase	patients with acute myocardial infarction within 12h from onset of ischemic chest pain	Parallel groups open USA, Germany

tenecteplase vs accelerated t-PA

ASSENT-2 , 1999 n=8461/8488 follow-up: 30d	Tenecteplase en IV bolus (dose en fonction du poids: 30 mg si <60 kg; 35 mg si poids entre 60 et 69.9 kg; 40 mg pour les 80-89.9 kg; 50 mg si >ou = 90 kg versus Alteplase en IV, bolus de 15 mg, puis 0.75 mg/kg (sans dpasser 50 mg) en 30 min puis 0.50 mg/kg (sans dpasser 35 mg) en 60 min	patients with acute myocardial infarction of less than 6 h duration	Parallel groups double blind 29 countries

accelerated t-PA vs APSAC

TAPS , 1992 n=199/202 follow-up:	front-loaded administration of rt-PA versus APSAC	patients with acute myocardial infarction.	Parallel groups open

∞

Trial	Treatments	Patients	Trials design and methods
TIMI 4 , 1994 n=NA follow-up: hospital stay	front-loaded rt-PA versus APSAC	patients with acute myocardial infarction	double blind
accelerated t-PA vs streptokinase			
GUSTO tPA Hiv , 1993 n=10396/20251 follow-up: 30 d	tPA acclr (15 mg en bolus, puis 0.75 mg/kg en 30 min sans dpasser 50 mg puis 0.5 mg/kg en 60 min sans dpasser 35 mg) + hparine en IV (5000 U en bolus, 1000 U/h (de prfrence 1200 U/h si >80 kg), poursuivi au moins 48 h) versus Streptokinase 1.5 MU en 60 min + hparine SC (12500 U 2 fois/j commence 4h aprs thrombolytique) combin streptokinase (1.5 MU en 60 min) + hparine en IV (5000 U en bolus, puis 1000 U/h (1200 U/h si >80 kg) poursuivi au moins 48 h)	Hommes et femmes	Parallel groups International 15 countries
anistreplase vs streptokinase			
TEAM 2 , 1991 n=183/176 follow-up:	anistreplase (30 units/2-5 min) versus streptokinase (1.5 million units/60 min	less than 76 years of age with electrocardiographic ST segment elevation who could be treated within 4 hours of symptom onset	double blind
APSAC vs streptokinase			
ISIS III (SK/APSAC) , 1992 n=13780/13773 follow-up: 6 mo	Streptokinase 1.5 MU infused over about 1 h versus anisoylated plasminogen-streptokinase activator complex (APSAC), anistreplase: 30 U over about 3 min	patients within 24 h of the onset of suspected acute myocardial infarction	Plan factoriel 3 (ou 4) *2 double blind International 17 countries
reteplase vs streptokinase			
INJECT , 1995 n=3004/3006 follow-up: 6 mo	Reteplase 2 bolus de 10 MU 30 min d'intervalle versus Streptokinase 1.5 MU en IV en 60 min	patients with symptoms and electrocardiographic criteria consistent with acute myocardial infarction within 12 h from onset of symptoms	Parallel groups double blind Europe
saruplase vs streptokinase			
COMPASS , 1998 n=1542/1547 follow-up: 1 y	saruplase 20-mg bolus and 60-mg infusion over 60 min versus streptokinase 1.5-MU infusion over 60 min	patients with symptoms compatible with those of acute myocardial infarction for <6 h	Parallel groups double blind
PRIMI (vs SK) , 1989 n=198/203 follow-up: ND	sarupalse 20 mg bolus followed by 60 mg infusion for 60 min versus 1.5 million IU streptokinase infused over 60 min	patients with acute myocardial infarction were within 4 h of onset of symptoms	Parallel groups double blind
t-PA vs streptokinase			

Trial	Treatments	Patients	Trials design and methods
International Study Group , 1990 n=10372/10396 follow-up: 6 mo	tPA 100 mg en IV en 3 h (10 mg en bolus, puis 50 mg en 1 h, puis 20 mg/h pendant 2 h) versus Streptokinase 1.5 MU en IV de 30 60 min	patients with suspected acute myocardial infarction of less than 6 h duration	Plan factoriel 2*2 double blind
Centre Illinois , 1993 n=123/130 follow-up:	t-PA 10 mg bolus, followed by 50 mg in the first hour, and 20 mg/hour for the next 2 hours versus SK 375 000 IU bolus, followed by 1 125 000 IU/1 hage/pj	patients with AMI within 3h from onset of chest pain	Parallel groups single blind USA
Cherng , 1992 n=59/63 follow-up: hospital stay	100 mg of rTPA over 3 hours (with early heparinization) versus 1,500,000 units of streptokinase over 1 hour	patients with acute myocardial infarction	Parallel groups open Taiwan
ECSG , 1985 n=64/65 follow-up:	0.75 mg rt-PA/kg over 90 min versus 1 500 000 IU streptokinase over 60 min	patients with acute myocardial infarction of less than 6 h duration	Parallel groups single-blind Europe
GISSI II , 1990 n=6182/6199 follow-up: 6 mo	alteplase 100 mg infused intravenously over 3 h versus streptokinase 1.5 MU infused intravenously over 30-60 min	patients with acute myocardial infarction within 6 h from onset of symptoms	Plan factoriel 2*2 open International 14 countries
ISIS III (SK/tPA) , 1992 n=13780/13746 follow-up: 6 mo	Streptokinase 1.5 MU en IV d'une heure versus tPA 0.04 MU/kg en IV en bolus d'1 min, puis 0.36 MU/kg en 1 h, puis 0.067 MU/kg/h pendant 3 h	Hommes et femmes	Plan factoriel 3 (ou 4) *2 double blind International 17 countries
PAIMS , 1989 n=86/85 follow-up:	intravenous cumulative dose of 100 mg rt-PA versus .5 million units streptokinase	patients with acute myocardial infarction less than 3 h old	Parallel groups open Italy
TIMI-1 , 1987 [NCT00000505] n=157/159 follow-up:	rt-PA, 40, 20, and 20 mg in successive hours versus SK 1.5 million units over 1 hr	patients with evolving acute myocardial infarction within 7 hr of the onset of symptoms	Parallel groups double blind USA
White , 1989 n=135/135 follow-up:	rt-PA 100 mg over three hours versus streptokinase 1.5 million units over 30 minutes	patients with AMI	Parallel groups double blind New Zealand

t-PA + streptokinase vs streptokinase

Trial	Treatments	Patients	Trials design and methods
GUSTO tPA-SK Hiv , 1993 n=10374/20251 follow-up: 30 d	tPA en IV 1 mg/kg, sans dpasser 90 mg, dont 10 % en bolus + streptokinase 1 MU en 60 min + hparine en IV (5000 U en bolus, 1000 U/h (de prfrence 1200 U/h si >80 kg), poursuivi au moins 48 h) versus Streptokinase 1.5 MU en 60 min + hparine SC (12500 U 2 fois/j commence 4h aprs thrombolytique) combin streptokinase (1.5 MU en 60 min) + hparine en IV (5000 U en bolus, puis 1000 U/h (1200 U/h si >80 kg) poursuivi au moins 48 h)	Hommes et femmes	Parallel groups International 15 countries

accelerated t-PA vs t-PA

Trial	Treatments	Patients	Trials design and methods
RAAMI , 1992 n=143/138 follow-up: hospital stay	100 mg of rt-PA accelerated 90-min regimen (15-mg bolus followed by 50 mg over 30 min, then 35 mg over 60 min) versus 100 mg of rt-PA standard 3-h infusion regimen (an initial 10-mg bolus followed by 50 mg for the 1st h, then 20 mg/h for 2 h	patients with acute myocardial infarction within 6h from onset of chest pain	Parallel groups open US

APSAC vs t-PA

Trial	Treatments	Patients	Trials design and methods
TEAM 3 , 1992 n=325 follow-up: 1 months	APSAC, 30 U/2 to 5 min versus rt-PA, 100 mg/3 h,	patient with ST elevation within 4h of the onset of symptoms	double blind

recombinant staphylokinase vs t-PA

Trial	Treatments	Patients	Trials design and methods
STAR , 1995 n=48/52 follow-up: 90 min	recombinant staphylokinase (10 or 20 mg given intravenously over 30 minutes) versus weight-adjusted rt-PA over 90 minutes	patients with evolving myocardial infarction of <6 hours' duration and with ST-segment elevation	Parallel groups open Belgium

saruplase vs t-PA

Trial	Treatments	Patients	Trials design and methods
SESAM , 1997 n=236/237 follow-up: hospital stay	saruplase 80 mg/hour versus alteplase 100 mg every 3 hours	patients with acute myocardial infarction	Parallel groups open Europe

t-PA + urokinase vs t-PA

Trial	Treatments	Patients	Trials design and methods
TAMI 5 (t-PA+uroK vs tPA) , 1991 n=194/191 follow-up:	t-PA + urokinase versus t-PA	patient with acute myocardial infarction	open

t-PA half dose vs t-PA

Trial	Treatments	Patients	Trials design and methods
KAMIT , 1991 n=109/107 follow-up: hospital stay	half-dose (50 mg) t-PA with streptokinase (1.5 MU) during 1 hour versus t-PA (100 mg) during 3 hours	patients within 6 hours of myocardial infarction	Parallel groups open USA

saruplase vs urokinase

Trial	Treatments	Patients	Trials design and methods
PRIMI (vs UK) , 1989 n=198 follow-up:	20 mg bolus followed by 60 mg infusion for 60 min versus 80 mg recombinant pro-urokinase	with a first acute myocardial infarction within 4 h of onset of symptoms	Parallel groups double blind
t-PA vs urokinase			
TAMI 5 (t-PA vs uroK) , 1991 n=191/190 follow-up:	accelerated t-PA 100mg over 3h versus urokinase IV bolus 1.5 MU followed by 1.5 MU over 90min	patient with acute myocardial infarction	open

References

APSIM, 1989:

USIM, 1991:

AIMS, 1988:

German Multicenter Trial, 1988:

EMERAS (7-12h), 1993:

EMERAS (all delay), 1993:

GISSI I, 1986:

ISAM, 1986:

ISIS 2 pilot, 1987:

ISIS-2 (SK), 1988:

Western Washington Intravenous Trial, 1988:

ASSET, 1988:

LATE, 1993:

TAMI 6, 1992:

COBALT, 1997:

InTIME-II, 2000:

GUSTO III, 1997:

RAPID-2, 1996:

ASSENT-2, 1999:

TAPS, 1992:

TIMI 4, 1994:

GUSTO tPA Hiv, 1993:

TEAM 2, 1991:

ISIS III (SK/APSAC), 1992:

INJECT, 1995:

COMPASS, 1998:

PRIMI (vs SK), 1989:

International Study Group, 1990:

Centre Illinois, 1993:

Cherng, 1992:

ECSG, 1985:

GISSI II, 1990:

ISIS III (SK/tPA), 1992:

PAIMS, 1989:

TIMI-1, 1987:

White, 1989:

GUSTO tPA-SK Hiv, 1993:

RAAMI, 1992:

TEAM 3, 1992:

STAR, 1995:

SESAM, 1997:

TAMI 5 (t-PA+uroK vs tPA), 1991:

KAMIT, 1991:

PRIMI (vs UK), 1989:

TAMI 5 (t-PA vs uroK), 1991:

5 immediate PCI after thrombolysis

Trial	Treatments	Patients	Trials design and methods
immediate systematic ballon angioplastyte vs no immediate angioplasty			
Belenkie , 1991 n=50/39 follow-up: 4 months	immediate PTCA versus delayed PTCA (18-38h)	patients with a patent infarct-related artery after thrombolytic therapy suitable for angioplasty	parallel group open Canada
ECSG , 1988 n=183/184 follow-up: 1 y	angioplasty as soon as possible (after rtPA) versus non-invasive strategy without immediate CA and PTCA	patients with acute myocardial infarction within 5 h after onset of symptoms	parallel group open Europe
Ellis , 1994 n=78/73 follow-up:	balloon angioplasty supplemented by further thrombolytic therapy as needed versus conservative therapy	patients with first anterior wall infarction treated with any accepted intravenous thrombolytic regimen and angiographically demonstrated to have an occluded infarct vessel within 8 hours of chest pain onset	
Erbel , 1989 n=103/103 follow-up: 3 years	combined intravenous and intracoronary streptokinase with immediate coronary angioplasty versus combined intravenous and intracoronary streptokinase without immediate coronary angioplasty	patients with acute transmural myocardial infarction	Parallel groups

Trial	Treatments	Patients	Trials design and methods
MERLIN (Sutton) , 2004 n=NA follow-up: 30 days	emergency coronary angiography with rescue PCI versus conservative treatment	patients with STEMI and failed fibrinolysis	Parallel groups
SHOCK (Hochman) , 1999 [NCT00000552] n=152/150 follow-up: 30 days (6y)	emergency revascularization versus initial medical stabilization	patients with cardiogenic shock complicating acute MI	Parallel groups open US
SWISS-SMASH , 1999 n=32/23 follow-up: 30 days (1y)	emergency angiography, followed immediately by revascularization when indicated versus initial medical management	Patients with acute myocardial infarction and early shock	Parallel groups open Europe
TAMI 1 pilot , 1987 n=99/98 follow-up: in hospital	Angioplasty within 120 min (after rtPA) versus defered CA (7-10 days) and angioplasty if indicated	patients with acute myocardial infarction.	parallel group open USA
TAMI-5 (Califf) , 1991 n=287/288 follow-up:	immediate catheterization with angioplasty for failed thrombolysis (90min after rtPA/urokinase) versus deferred predischarge catheterization on days 5-10, no PTCA planned	patient with acute myocardial infarction	Factorial plan
TIMI 2A , 1988 n=195/194 follow-up: 21 days	CA within 120 min of the start of the rtPA infusion. PTCA whether the artery is open or closed versus CA within 18-48hrs. PTCA only if artery open (TIMI 2 or 3)	patient thrombolyzed for a AMI	parallel group open USA
Topol , 1987 n=15/13 follow-up: in hospital	immediate PTCA versus no PTCA	patients with evolving transmural myocardial infarction	parallel group open USA

systematic PCI (+stent) vs no systematic PCI

Trial	Treatments	Patients	Trials design and methods
CAPITAL AMI , 2005 n=86/84 follow-up: 6 months	TNK-facilitated angioplasty versus TNK alone	patients with high-risk ST-segment elevation myocardial infarction	Parallel groups
GRACIA-1 , 2004 n=248/251 follow-up: 12 months	angiography and intervention if indicated within 24 h of thrombolysis versus ischaemia-guided conservative approach	patients with thrombolysed STEMI (with recombinant tissue plasminogen activator)	Parallel groups
PRAGUE , 2000 n=100/99 follow-up: 12 months	thrombolysis during immediate transportation for coronary angioplasty versus thrombolysis in a community hospital	patients with acute ST elevation myocardial infarction presenting to community hospitals	

Trial	Treatments	Patients	Trials design and methods
SIAM III , 2002 n=82/81 follow-up: 6 months	immediate stenting after thrombolysis versus conservative treatment	patients receiving thrombolysis in AMI (<12 h)	Parallel groups Germany
WEST , 2006 n=104/100 follow-up: 30 days	TNK and mandatory invasive study <= 24 h, including rescue PCI for reperfusion failure versus tenecteplase (TNK) and usual care	STEMI patients (>4 mm ST-elevation/deviation) within 6 h of symptom onse	Parallel groups Canada

References

Belenkie, 1991:
ECSG, 1988:
Ellis, 1994:
Erbel, 1989:
MERLIN (Sutton), 2004:
SHOCK (Hochman), 1999:
SWISS-SMASH, 1999:
TAMI 1 pilot, 1987:
TAMI-5 (Califf), 1991:
TIMI 2A, 1988:
Topol, 1987:
CAPITAL AMI, 2005:
GRACIA-1, 2004:
PRAGUE, 2000:
SIAM III, 2002:
WEST, 2006:

6 Prehospital thrombolysis

Trial	Treatments	Patients	Trials design and methods
Prehospital thrombolysis vs at hospital thrombolysis			
EMIP , 1993 n=2750/2719 follow-up: ND	-	-	ND
GREAT , 1994 n=163/148 follow-up: ND	-	-	ND
MITI , 1993 [NCT00000468] n=175/175 follow-up: ND	-	-	ND

Trial	Treatments	Patients	Trials design and methods
Roth , 1990 n=72/44	-	-	
Barbash , 1990 n=NA	-	-	
Castaigne , 1987 n=NA	-	-	
Mcneill , 1989 n=NA	-	-	
Schofer , 1990 n=40/38	-	-	
Castaigne , 1989 n=57/43	-	-	
TEAHAT , 1990 n=NA follow-up: ND	-	-	ND

References

EMIP, 1993:

GREAT, 1994:

MITI, 1993:

Roth, 1990:

Barbash, 1990:

Castaigne, 1987:

Mcneill, 1989:

Schofer, 1990:

Castaigne , 1989:

TEAHAT, 1990:

7   primary PCI

Trial	Treatments	Patients	Trials design and methods
primary ballon angioplasty vs accelerated t-PA			
Ribichini , 1996 n=24/26 follow-up: discharge	primary PTCA versus accelerated alteplase 90 min (15 mg IV bolus followed by an infusion of 0.75 mg/kg over 30min not to exceed 50mg, and then 0.5 mg/kg over the next 60min not to exceed 35mg for a total maximun of 100mg)	-	Parallel groups open Italy

Trial	Treatments	Patients	Trials design and methods
Garcia , 1997 n=95/94 follow-up: 30 d	primary PTCA versus accelerated t-PA 90 min (15 mg IV bolus followed by an infusion of 0.75 mg/kg over 30min not to exceed 50mg, and then 0.5 mg/kg over the next 60min not to exceed 35mg for a total maximun of 100mg)	patients with anterior AMI	Parallel groups open Spain
GUSTO 2B , 1997 n=573/565 follow-up: 30 d	primary PTCA versus accelerated t-PA 90 min (15 mg IV bolus followed by an infusion of 0.75 mg/kg over 30min not to exceed 50mg, and then 0.5 mg/kg over the next 60min not to exceed 35mg for a total maximun of 100mg)	patients within 12 hours of acute myocardial infarction (with ST-segment elevation on the electrocardiogram)	factorial design open USA, Europe, Australia
DANAMI-2 , 1997 n=NA follow-up: 2.4y	angioplasty versus accelerated treatment with intravenous alteplase	patients who received thrombolytic treatment for a first acute myocardial infarction and with inducible myocardial ischemia (either symptomatic angina pectoris presenting spontaneously >36 hours after admission or during a predischarge exercise test or ST changes during exercise compatible with ischemia)	Parallel groups open

primary PCI vs accelerated t-PA

Trial	Treatments	Patients	Trials design and methods
C-PORT , 2002 n=225/226 follow-up: 6 months	primary PCI without on-site cardiac surgery versus accelerated tissue plasminogen activator	thrombolytic-eligible patients with acute MI of less than 12 hours' duration associated with ST-segment elevation	Parallel groups open USA

primary stenting vs accelerated t-PA

Trial	Treatments	Patients	Trials design and methods
STAT , 2001 n=62/61 follow-up: 6 months	primary stenting versus accelerated t-PA	patients with acute ST-elevation myocardial infarction	Parallel groups open

facilitated stenting vs alteplase

Trial	Treatments	Patients	Trials design and methods
STOPAMI 1 , 2000 n=71/69 follow-up: 6 months	stent plus abciximab versus intravenous alteplase	patients with acute myocardial infarction	Parallel groups open

primary stenting vs balloon angioplasty

Trial	Treatments	Patients	Trials design and methods
Zwolle 5 (Suryapranata) , 1998 n=112/115 follow-up: 12 months	Stent Palmaz-Schatz versus balloon angioplasty	Patients with acute myocardial infarction	Parallel groups open
FRESCO , 1998 n=75/75 follow-up: 12 months	elective stenting after successful primary PTCA versus no further intervention after successful primary PTCA	patient with successful primary PTCA	Parallel groups open

Trial	Treatments	Patients	Trials design and methods
GRAMI (Rodriguez) , 1998￼ n=52/52￼ follow-up: 12 months	balloon angioplasty followed electively with Gianturco Roubin II stents versus conventional balloon angioplasty	patients with acute myocardial infarction within 24 hours after onset	Parallel groups open
PASTA (Saito) , 1999 n=67/70 follow-up: 12 months	Stent Palmaz-Schatz versus primary balloon angioplasty	patients with AMI within 12 hr from onset	Parallel groups open
stent-PAMI (Grines) , 1999 n=452/448 follow-up: 12 months	angioplasty with Stent Heparin-coated versus angioplasty alone	patients with acute myocardial infarction and with vessels suitable for stenting	Parallel groups open
STENTIM-2 (Maillard) , 2000￼ n=101/110 follow-up: 12 months	systematic stenting with Stent Wiktor versus conventional balloon angioplasty	patients with AMI <12 h from symptom onset, with an occluded native coronary artery	Parallel groups open
PSSAAMI (Scheller) , 2001 n=44/44 follow-up: 24 months	Stent Wiktor GX versus primary angioplasty	patients within 24 hours after the onset of acute myocardial infarction	Parallel groups open
Jaksch , 1998 n=231/231 follow-up: 65279;6 months	-	-	Parallel groups open
PRISAM (Kawashima) , 1999 n=110/112 follow-up: 65279;6 months	-	-	Parallel groups open
CADILLAC (no abciximab) , 2002 n=512/518 follow-up: 12 months	stenting alone with the MultiLink stent versus PTCA alone	patients with acute myocardial infarction	Parallel groups open
CADILLAC abciximab. , 2002 n=524/528 follow-up: 12 months	stenting plus abciximab therapy versus PTCA plus abciximab therapy	patients with acute myocardial infarction	Parallel groups open
ZWOLLE 6 , 2005 n=785/763 follow-up: 12 months	stenting versus balloon angioplasty	unselected patients with STEMI	Parallel groups open
STOPAMI 3 , 2004 n=305/306 follow-up: 6 months	coronary artery stenting versus PTCA	patients with AMI ineligible for thrombolysis (lack of ST-segment elevation on the electrocardiogram, late presentation >12 h after symptom onset, and contraindications to thrombolysis)	Parallel groups open
primary ballon angioplasty vs duteplase			
DeWood , 1989 n=46/44 follow-up: 30 d	primary PTCA versus duteplase 0.5 MU/kg for 1 h then 0.7 MU/kg/h for 3h	-	Parallel groups open USA

Trial	Treatments	Patients	Trials design and methods
Gibbons , 1993 n=47/56 follow-up: discharge	primary PTCA versus duteplase 0.6 MU/kg over 5h	patients with acute myocardial infarction	Parallel groups open USA

primary stenting vs immediate thrombolysis

STOPAMI 2 , 2002 n=81/81 follow-up:	stenting combined with abciximab versus fibrinolysis by alteplase combined with abciximab	patients with acute myocardial infarction within 12 h of onset of symptoms	Parallel groups open

transfer for primary angioplasty vs immediate thrombolysis

AIR-PAMI , 2002 n=71/66 follow-up:	Transfer for Primary Angioplasty versus immediate thrombolysis (various thrombolytic)	Patients with high-risk AMI (age >70 years, anterior MI, Killip class II/III, heart rate >100 beats/min or systolic BP <100 mm Hg), eligible for thrombolytic therapy	Parallel groups open
DANAMI-2 , 2003 n=567/562 follow-up: 30 days	Transfer for Primary Angioplasty versus immediate thrombolysis with tPA (accelared infusion)	patients with myocardial infarction with ST-segment elevation	Parallel groups open
PRAGUE-2 , 2003 n=429/421 follow-up: 30 days	immediate transport for primary percutaneous coronary intervention versus immediate thrombolysis with streptokinase	patients with acute ST elevation myocardial infarction presenting within <12 h to the nearest community hospital without a catheter laboratory	Parallel groups open

primary ballon angioplasty vs intracoronary streptokinase

O'Neill , 1986 n=NA follow-up:	coronary angioplasty versus intracoronary streptokinase	patients within 12 hours of their first symptoms of acute myocardial infarction	Parallel groups open

primary ballon angioplasty vs streptokinase

Zwolle , 1994 n=152/149 follow-up: discharge	primary PTCA versus streptokinase 1.5 M IU over 1h	patients with acute myocardial infarction	Parallel groups open The Netherland
Ribeiro , 1993 n=50/50 follow-up: discharge	primary PTCA versus streptokinase 1.2 M IU over 1h	patients with ST segment elevation within 6 h of the onset of chest pain	Parallel groups open Brazil
Grinfeld , 1996 n=54/58 follow-up: 30 d	primary PTCA versus streptokinase 1.5 M IU over 1h	-	Parallel groups open Argentina
Zijlstra , 1997 n=45/50 follow-up: 6 months	primary PTCA versus streptokinase 1.5 M IU over 1h	atients with acute myocardial infarction	Parallel groups open The Netherland

Trial	Treatments	Patients	Trials design and methods
Zijlstra , 1993 n=70/72 follow-up:	immediate coronary angioplasty (without previous thrombolytic therapy) versus intravenous streptokinase	patients with acute myocardial infarction	Parallel groups open
Akhras , 1997 n=42/45 follow-up:	primary angioplasty versus streptokinase	patient within 12hr from onset of AMI	Parallel groups open Saudi Arabia
primary ballon angioplasty vs t-PA			
PAMI , 1993 n=195/200 follow-up: discharge	primary PTCA versus t-PA 100mg (or 1.25mg/kg for patients weighting less than 65kg) over 3 h	patients who presented within 12 hours of the onset of myocardial infarction	Parallel groups open USA,Europe
primary ballon angioplasty vs tenecteplase			
TRIANA , 2009 [NCT00257309] n=132/134 follow-up: 30 days (12 months)	Tenecteplase + UFH (+/- clopidogrel) versus Primary angioplasty	>=75 years old with ST-segment elevation or LBBB AMI <6 hours of evolution without contraindications for thrombolytic therapy	Parallel groups open
primary PCI vs Thrombolysis			
senior PAMI , 2005 [NCT00136929] n=252/229 follow-up: 30 days	primary percutaneous coronary intervention versus intravenous thrombolytic therapy	elderly (age >= 70 years) patients with acute myocardial infarction	Parallel groups Open

References

Ribichini, 1996:

Garcia, 1997:

GUSTO 2B, 1997:

DANAMI-2, 1997:

C-PORT, 2002:

STAT, 2001:

STOPAMI 1, 2000:

Zwolle 5 (Suryapranata), 1998:

FRESCO, 1998:

GRAMI (Rodriguez), 1998:

PASTA (Saito), 1999:

stent-PAMI (Grines), 1999:

STENTIM-2 (Maillard), 2000:

PSSAAMI (Scheller), 2001:

Jaksch, 1998:

PRISAM (Kawashima), 1999:

CADILLAC (no abciximab), 2002:

CADILLAC abciximab., 2002:

ZWOLLE 6, 2005:

STOPAMI 3, 2004:

DeWood, 1989:

Gibbons, 1993:

STOPAMI 2, 2002:

AIR-PAMI , 2002:

DANAMI-2 , 2003:

PRAGUE-2 , 2003:

O'Neill, 1986:

Zwolle, 1994:

Ribeiro, 1993:

Grinfeld, 1996:

Zijlstra, 1997:

Zijlstra , 1993:

Akhras, 1997:

PAMI, 1993:

TRIANA, 2009:

senior PAMI, 2005:

8   transfer for primary angioplasty

Trial	Treatments	Patients	Trials design and methods
primary angioplasty vs immediate thrombolysis			
MAASTRICHT (Vermeer) , 1999 n=75/75 follow-up:	Transfer for primary PTCA versus immediate thrombolysis with tPA	patients with acute myocardial infarction initially admitted to a hospital without PTCA facilities	open
PRAGUE-1 , 2000 n=101/99 follow-up: 30 days	immediate transportation for primary angioplasty without pre-treatment with thrombolysis versus immediate thrombolysis with streptokinase	patients with acute myocardial infarction, presenting within 6 h of symptom onset at community hospitals without a catheterization laboratory	open
AIR-PAMI , 2002 n=71/66 follow-up:	Transfer for Primary Angioplasty versus immediate thrombolysis (various thrombolytic)	Patients with high-risk AMI (age >70 years, anterior MI, Killip class II/III, heart rate >100 beats/min or systolic BP <100 mm Hg), eligible for thrombolytic therapy	open
CAPTIM , 2002 n=421/419 follow-up:	Transfer for Primary Angioplasty versus prehospital fibrinolysis with accelerated alteplase	patients within 6 h of acute myocardial infarction with ST-segment elevation, initially managed by mobile emergency-care units	open

Trial	Treatments	Patients	Trials design and methods
DANAMI-2 , 2003 n=567/562 follow-up: 30 days	Transfer for Primary Angioplasty versus immediate thrombolysis with tPA (accelared infusion)	patients with myocardial infarction with ST-segment elevation	Parallel groups open
PRAGUE-2 , 2003 n=429/421 follow-up: 30 days	immediate transport for primary percutaneous coronary intervention versus immediate thrombolysis with streptokinase	patients with acute ST elevation myocardial infarction presenting within <12 h to the nearest community hospital without a catheter laboratory	open

thrombolysis + angioplasty vs immediate thrombolysis

Trial	Treatments	Patients	Trials design and methods
NORDISTEMI , 2009 [NCT00161005] n=134/132 follow-up: 1y	transfer for immediate coronary angiography and intervention versus concervative strategy	patients with STEMI of less than 6 hours of duration and more than 90 minutes expected time delay to PCI	Parallel groups open Norway
PRAGUE-1 (thrombolysis+PTCA) , 2000 n=100/99 follow-up: 30 days	thrombolytic therapy during transportation to angioplasty versus immediate thrombolysis with streptokinase	patients with acute myocardial infarction, presenting within 6 h of symptom onset at community hospitals without a catheterization laboratory	Parallel groups open Czech Republic
CARESS , 2008 n=NA follow-up: 30 days	immediate transfer for PCI after half-dose reteplase, abciximab, heparin, and aspirin versus half-dose reteplase, abciximab, heparin, and aspirin, transfer for PCI only if they had persistent ST elevation at 90 minutes (rescue PCI)	STEMI patients under 75 years old within 12 hours of symptom onset who had been admitted to hospitals without PCI facilities	open France, Italy, and Poland
CAPITAL AMI , 2005 n=86/84 follow-up: 6 months	full-dose tenecteplase (TNK) plus PCI versus thrombolysis alone	high-risk MI patients within six hours of symptom onset	Parallel groups open US
TRANSFER-AMI , 2008 *ongoing* [NCT00164190] n=NA follow-up: 30 days	pharmacoinvasive strategy (transfer for PCI within six hours of fibrinolysis) versus standard treatment after fibrinolysis (rescue PCI for failed reperfusion, with elective PCI encouraged for successfully reperfused patients after 24 hours)	patients with high-risk STEMI	Parallel groups open

References

MAASTRICHT (Vermeer), 1999:

PRAGUE-1, 2000:

AIR-PAMI, 2002:

CAPTIM, 2002:

DANAMI-2, 2003:

PRAGUE-2, 2003:

NORDISTEMI, 2009:

PRAGUE-1 (thrombolysis+PTCA), 2000:
CARESS, 2008:
CAPITAL AMI, 2005:
TRANSFER-AMI, 2008:

9 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.